Literature DB >> 28361066

Emerging treatments for hemophilia: patients and their treaters spoilt for choice, but laboratories face a difficult path?

Emmanuel J Favaloro1, Giuseppe Lippi2.   

Abstract

Entities:  

Year:  2017        PMID： 28361066      PMCID： PMC5360607          DOI： 10.21037/atm.2017.02.34

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  13 in total

1.  One-stage clotting versus chromogenic assays for assessing recombinant factor VIII: two faces of a haemostasis coin.

Authors:  Giuseppe Lippi; Massimo Franchini; Emmanuel J Favaloro
Journal:  Blood Coagul Fibrinolysis       Date:  2009-01       Impact factor: 1.276

Review 2.  Targeting factor replacement therapy in severe hemophilia: which level is important?

Authors:  Kathelijn Fischer; Erik Berntorp
Journal:  Semin Thromb Hemost       Date:  2015-10-09       Impact factor: 4.180

Review 3.  Problems and solutions in laboratory testing for hemophilia.

Authors:  Emmanuel J Favaloro; Piet Meijer; Ian Jennings; John Sioufi; Roslyn A Bonar; Dianne P Kitchen; Geoffrey Kershaw; Giuseppe Lippi
Journal:  Semin Thromb Hemost       Date:  2013-09-11       Impact factor: 4.180

Review 4.  Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.

Authors:  Steve Kitchen; Stefan Tiefenbacher; Robert Gosselin
Journal:  Semin Thromb Hemost       Date:  2017-03-06       Impact factor: 4.180

Review 5.  Potency labeling of novel factor VIII and factor IX concentrates: past experience and current strategy.

Authors:  Anthony R Hubbard
Journal:  Semin Thromb Hemost       Date:  2015-02-19       Impact factor: 4.180

6.  Laboratory monitoring of direct oral anticoagulants (DOACs)-The perfect storm?

Authors:  Giuseppe Lippi; Emmanuel J Favaloro
Journal:  Ann Transl Med       Date:  2017-01

7.  Laboratory economics. Risk or opportunity?

Authors:  Giuseppe Lippi; Mario Plebani
Journal:  Clin Chem Lab Med       Date:  2016-11-01       Impact factor: 3.694

Review 8.  Prophylaxis for Hemophilia in the Era of Extended Half-Life Factor VIII/Factor IX Products.

Authors:  Erik Berntorp; Nadine G Andersson
Journal:  Semin Thromb Hemost       Date:  2016-04-20       Impact factor: 4.180

Review 9.  Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy.

Authors:  Riten Kumar; Amy Dunn; Manuel Carcao
Journal:  Semin Thromb Hemost       Date:  2016-01-15       Impact factor: 4.180

Review 10.  Safety of Switching Factor VIII Products in the Era of Evolving Concentrates: Myths and Facts.

Authors:  Antonio Coppola; Emiliana Marrone; Paolo Conca; Ernesto Cimino; Rosaria Mormile; Erminia Baldacci; Cristina Santoro
Journal:  Semin Thromb Hemost       Date:  2016-06-03       Impact factor: 4.180
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.